200 related articles for article (PubMed ID: 33294262)
1. GOLM1 upregulates expression of PD-L1 through EGFR/STAT3 pathway in hepatocellular carcinoma.
Yan J; Zhou B; Guo L; Chen Z; Zhang B; Liu S; Zhang W; Yu M; Xu Y; Xiao Y; Zhou J; Fan J; Li H; Ye Q
Am J Cancer Res; 2020; 10(11):3705-3720. PubMed ID: 33294262
[TBL] [Abstract][Full Text] [Related]
2. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
Ke MY; Xu T; Fang Y; Ye YP; Li ZJ; Ren FG; Lu SY; Zhang XF; Wu RQ; Lv Y; Dong J
Cancer Lett; 2021 Aug; 513():14-25. PubMed ID: 33992711
[TBL] [Abstract][Full Text] [Related]
3. GOLM1 exacerbates CD8
Chen J; Lin Z; Liu L; Zhang R; Geng Y; Fan M; Zhu W; Lu M; Lu L; Jia H; Zhang J; Qin LX
Signal Transduct Target Ther; 2021 Nov; 6(1):397. PubMed ID: 34795203
[TBL] [Abstract][Full Text] [Related]
4. FAT10 induces immune suppression by upregulating PD-L1 expression in hepatocellular carcinoma.
Wang Q; Tan W; Zhang Z; Chen Q; Xie Z; Yang L; Tang C; Zhuang H; Wang B; Jiang J; Ma X; Wang W; Hua Y; Shang C; Chen Y
Apoptosis; 2024 Jun; ():. PubMed ID: 38824477
[TBL] [Abstract][Full Text] [Related]
5. Protein tyrosine phosphatase receptor type delta (PTPRD) suppresses the expression of PD-L1 in human hepatocellular carcinoma by down-regulating STAT3.
Meng Q; Tian J; Qin F; Huang X; Zhu D; Xiang B; Dong M
Transl Cancer Res; 2020 Sep; 9(9):5574-5584. PubMed ID: 35117921
[TBL] [Abstract][Full Text] [Related]
6. GOLM1 is related to the inflammatory/immune nature of uveal melanoma and acts as a promising indicator for prognosis and immunotherapy response.
Liang X; Yin Y; Li N
Front Genet; 2022; 13():1051168. PubMed ID: 36468024
[No Abstract] [Full Text] [Related]
7. Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway.
Ren D; Zhao J; Sun Y; Li D; Meng Z; Wang B; Fan P; Liu Z; Jin X; Wu H
J Exp Clin Cancer Res; 2019 Dec; 38(1):485. PubMed ID: 31818309
[TBL] [Abstract][Full Text] [Related]
8. mTOR/miR-145-regulated exosomal GOLM1 promotes hepatocellular carcinoma through augmented GSK-3β/MMPs.
Gai X; Tang B; Liu F; Wu Y; Wang F; Jing Y; Huang F; Jin D; Wang L; Zhang H
J Genet Genomics; 2019 May; 46(5):235-245. PubMed ID: 31186161
[TBL] [Abstract][Full Text] [Related]
9. GOLM1 Modulates EGFR/RTK Cell-Surface Recycling to Drive Hepatocellular Carcinoma Metastasis.
Ye QH; Zhu WW; Zhang JB; Qin Y; Lu M; Lin GL; Guo L; Zhang B; Lin ZH; Roessler S; Forgues M; Jia HL; Lu L; Zhang XF; Lian BF; Xie L; Dong QZ; Tang ZY; Wang XW; Qin LX
Cancer Cell; 2016 Sep; 30(3):444-458. PubMed ID: 27569582
[TBL] [Abstract][Full Text] [Related]
10. Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma.
Chun HW; Hong R
Oncol Lett; 2019 Jun; 17(6):5487-5498. PubMed ID: 31186768
[TBL] [Abstract][Full Text] [Related]
11. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer.
Zhang N; Zeng Y; Du W; Zhu J; Shen D; Liu Z; Huang JA
Int J Oncol; 2016 Oct; 49(4):1360-8. PubMed ID: 27499357
[TBL] [Abstract][Full Text] [Related]
12. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
13. PKM2-Induced the Phosphorylation of Histone H3 Contributes to EGF-Mediated PD-L1 Transcription in HCC.
Wang X; Liang C; Yao X; Yang RH; Zhang ZS; Liu FY; Li WQ; Pei SH; Ma J; Xie SQ; Fang D
Front Pharmacol; 2020; 11():577108. PubMed ID: 33324209
[TBL] [Abstract][Full Text] [Related]
14. FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.
Li P; Huang T; Zou Q; Liu D; Wang Y; Tan X; Wei Y; Qiu H
J Immunol; 2019 May; 202(10):3065-3075. PubMed ID: 30979816
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma.
Jiang G; Shi L; Zheng X; Zhang X; Wu K; Liu B; Yan P; Liang X; Yu T; Wang Y; Cai X
Aging (Albany NY); 2020 Jun; 12(12):11466-11484. PubMed ID: 32579541
[TBL] [Abstract][Full Text] [Related]
16. Recent advances of GOLM1 in hepatocellular carcinoma.
Yan J; Zhou B; Li H; Guo L; Ye Q
Hepat Oncol; 2020 Jun; 7(2):HEP22. PubMed ID: 32647567
[TBL] [Abstract][Full Text] [Related]
17. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.
Liu J; Liu Y; Meng L; Liu K; Ji B
Oncol Rep; 2017 Aug; 38(2):899-907. PubMed ID: 28627705
[TBL] [Abstract][Full Text] [Related]
18. Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma
Yu C; Zhang X; Wang M; Xu G; Zhao S; Feng Y; Pan C; Yang W; Zhou J; Shang L; Ma Y
Front Oncol; 2023; 13():1198118. PubMed ID: 37324014
[TBL] [Abstract][Full Text] [Related]
19. Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells.
Ke M; Zhang Z; Xu B; Zhao S; Ding Y; Wu X; Wu R; Lv Y; Dong J
Int Immunopharmacol; 2019 Oct; 75():105824. PubMed ID: 31437792
[TBL] [Abstract][Full Text] [Related]
20. Expression of GOLM1 correlates with prognosis in human hepatocellular carcinoma.
Chen MH; Jan YH; Chang PM; Chuang YJ; Yeh YC; Lei HJ; Hsiao M; Huang SF; Huang CY; Chau GY
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S616-24. PubMed ID: 23838921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
